aTyr Pharma, which is developing restorative protein therapeutics for rare muscular dystrophies, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
aTyr notes that September 2013 biotech Acceleron Pharma (XLRN; +128%) is developing a protein therapeutic designed to increase muscle mass in patients with neuromuscular disorders.
The San Diego, CA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol LIFE. aTyr Pharma initially filed confidentially on December 22, 2014. J.P. Morgan and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
